Role of bromocriptine through enteral route for decreasing neurogenic fever in severe head Injury patients in Trauma Intensive Care Unit.

Efficacy of prophylactic enteral bromocriptine in reducing the neurogenic fever in severe Traumatic Brain Injury patients in the Trauma Intensive Care Unit - A Randomized placebo Controlled Study - Nil

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056344

Enrollment

100

Registered

2023-08-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S06- Intracranial injury Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: TABLET BROMOCRIPTINE: Will receive tablet bromocriptine 5 mg nasogastric/orogastric tube BD for five days within 24 hours of head injury admitted into the hospital triage. Control Inter

Eligibility

Inclusion criteria

Inclusion criteria: Isolated cases of severe Traumatic brain injury patients with diagnosis of sub arachnoid hemorrhage, diffuse axonal injury, frontal contusion, intraventricular hemorrhage admitted in the trauma centre within 24 hours of head injury

Exclusion criteria

Exclusion criteria: 1. Bromocriptine hypersensitivity or allergy, Known contraindication to bromocriptine— known ergot alkaloid hypersensitivity, known history of syncopal migraine. 2. Contraindication to oesophageal temperature measurement 3. Current diagnosis of systemic manifestations like acute and chronic Liver Failure, Renal Failure 4. Currently being treated with intra or extravascular therapeutic hypothermia – or where therapeutic hypothermia treatment is anticipated during the study period 5. Hyperthermic syndromes: heat stroke, evidence of thyrotoxicosis, malignant hyperthermia, Neuroleptic malignant syndrome, or other drug-induced hyperthermia. 6. Pregnancy or lactating women 7. Extracorporeal blood circuit therapies: replacement therapy, extracorporeal life support. (Ventricular assist device, extracorporeal membrane oxygenation) during the study period. 8. Patients already taking bromocriptine or dopamine antagonist

Design outcomes

Primary

Measure	Time frame
To compare the incidence of neurogenic feverTimepoint: days 0-14	—

Secondary

Measure	Time frame
To compare the severity & frequency of fever • To compare the time of fever onset • To monitor the adverse effects of bromocriptine • To compare the duration of hospital stay in the ICU • To compare the escalation of antibioticsTimepoint: days 0-14	—

Countries

India

Contacts

Public ContactDr Amrita Rath

Institute of medical sciences,banaras hindu university

ghanshyambhu1976@gmail.com9838894169

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026